Advertisement
Advertisement
USNA
USANA Health Sciences Inc
12.94
USDSponsored
-0.22
-1.67%
Nov 20, 15:59 UTC -5
Closed
After-Market
13.25
+0.31
+2.40%
USANA Health Sciences Inc (USNA) Earnings
USNA Earnings Reports
Positive Surprise Ratio
USNA beat 25 of 43 last estimates.
58%
Next Report
Date of Next Report
Feb 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$224.10M
/$0.12
Implied change from Q3 26 (Revenue/ EPS)
+8.85%
/-209.09%
Implied change from Q4 25 (Revenue/ EPS)
-0.93%
/-80.00%
USANA Health Sciences Inc earnings per share and revenue
On Nov 03, 2026, USNA reported earnings of -0.11 USD per share (EPS) for Q3 26, missing the estimate of 0.11 USD, resulting in a -198.04% surprise. Revenue reached 205.88 million, compared to an expected 222.45 million, with a -7.45% difference. The market reacted with a -3.63% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.12 USD, with revenue projected to reach 224.10 million USD, implying an decrease of -209.09% EPS, and increase of 8.85% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were USANA Health Sciences Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, USANA Health Sciences Inc reported EPS of -$0.11, missing estimates by -198.04%, and revenue of $205.88M, -7.45% below expectations.
How did the market react to USANA Health Sciences Inc's Q3 2026 earnings?
The stock price moved down -3.63%, changed from $14.87 before the earnings release to $14.33 the day after.
When is USANA Health Sciences Inc expected to report next?
The next earning report is scheduled for Feb 10, 2027.
What are the forecasts for USANA Health Sciences Inc's next earnings report?
Based on --
analysts, USANA Health Sciences Inc is expected to report EPS of $0.12 and revenue of $224.10M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.